In one paragraphArticle in Acta neurochirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Angel BuenoVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.ORCID 0009-0009-6256-1624 Andrea Becerril-GaitanVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.ORCID 0000-0003-4606-5646 Collins MokuaVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.ORCID 0009-0000-1057-9448 Kristina Ramirez-GarciaVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.ORCID 0009-0003-6962-1227 Justin NguyenVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.ORCID 0009-0007-0659-3256 Faris ShakerVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.ORCID 0000-0003-4462-5232 Tien NguyenVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.
Antonio DonoVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.ORCID 0000-0002-8041-8399 Spiros BlackburnVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.ORCID 0000-0003-2902-5079 Peng Roc ChenVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.ORCID 0000-0001-8438-132X Mark DannenbaumVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.ORCID 0000-0001-6999-438X H Alex ChoiVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.ORCID 0000-0001-7218-832X Arthur L DayVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.
Jacques J MorcosVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA.
Ching-Jen ChenVivian L. Smith Department of Neurosurgery, Mcgovern Medical School, The University of Texas Health Science Center at Houston, 6400 Fannin Street, Suite #2800, Houston, TX, 77030, USA. Ching-Jen.Chen@uth.tmc.edu.ORCID 0000-0002-7830-9273 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundMetformin is widely prescribed and has neuroprotective effects in animals, but its impact on brain injury after aneurysmal subarachnoid hemorrhage (aSAH) in humans is unclear.
methodsThis single-center retrospective review assessed patients with aSAH from 2009 to 2023, categorizing them based on pre-admission metformin use. The primary outcome was delayed cerebral ischemia (DCI), while secondary outcomes included in-hospital mortality, rebleeding, angiographic cerebral vasospasm (CVS), and favorable modified Rankin Scale (mRS) scores at discharge and the 3-month follow-up. Outcomes were analyzed using logistic regression. Sensitivity analysis was performed after excluding patients receiving comfort care.
resultsA total of 900 patients were included (47 metformin and 853 non-metformin). DCI rates were similar between groups (38.3% vs. 29.3%, aOR = 1.06 [0.49-2.28]). Rebleeding rates were 4.3% for metformin users and 5.6% for non-users (aOR = 0.47 [0.09-2.51]). In-hospital mortality was 4.3% in metformin users vs. 9.7% in non-users (aOR = 0.47 [0.08-2.84]). Angiographic CVS was 38.3% in metformin users and 52.8% in non-users (aOR = 0.49 [0.23-1.05]), and at 7 days, CVS was 29.8% vs. 47.6% (aOR = 0.46 [0.21-1.01]). Sensitivity analysis showed similar DCI rates (39.1% vs. 30.9%, aOR = 0.98 [0.45-2.15]) but lower CVS at 7 days for metformin users (aOR = 0.44 [0.20-0.98]).
conclusionMetformin use before aSAH did not significantly affect the risk of DCI or CVS. However, after excluding comfort care patients, the findings are highly speculative of reduced CVS risk at 7 days post-aSAH. Rebleeding and mortality rates were similar across groups. Future research with larger, multi-institutional datasets is needed to better understand metformin's impact, particularly during and after aSAH.
Indexed as
Brain IschemiaHypoglycemic AgentsMetforminSubarachnoid HemorrhageVasospasm, IntracranialAdultAgedFemaleHospital MortalityHumansMaleMiddle AgedRecurrenceRetrospective StudiesTreatment OutcomeHypoglycemic AgentsMetforminAneurysmal subarachnoid hemorrhageCerebral vasospasmDelayed cerebral ischemiaMortalityRebleeding
Identifiers
PMID40208362
PMCPMC11985594
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390